Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 02/13/14 | 8-K | Current report filing |
|
6 | |
| 02/06/14 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
105 | |
| 02/05/14 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 02/05/14 | EFFECT | Notice of Effectiveness |
|
1 | |
| 02/04/14 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 01/31/14 | S-1/A | General form of registration statement for all companies including face-amount certificate companies |
|
   |
124 |
| 01/24/14 | 8-K | Current report filing |
|
3 | |
| 01/16/14 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 01/13/14 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
|
37 |
| 12/06/13 | 8-K/A | Current report filing |
|
4 |
